ID

775

Description

CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

Link

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

Keywords

  1. 8/26/12 8/26/12 -
  2. 7/8/15 7/8/15 -
  3. 7/8/15 7/8/15 -
Uploaded on

August 26, 2012

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00041119 Eligibility - CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST - 2039130v3.0

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

Unnamed1
Description

Unnamed1

CALGB Study No.
Description

CALGBProtocolNumber

Data type

text

CALGB Patient ID
Description

CALGBPatientID

Data type

text

Unnamed2
Description

Unnamed2

Patient's Name
Description

Patient'sName

Data type

text

Participating Group
Description

ParticipatingGroup

Data type

text

Alias
NCI Thesaurus ObjectClass
C17005
UMLS 2011AA ObjectClass
C1257890
NCI Thesaurus Property
C25364
UMLS 2011AA Property
C0600091
Patient Hospital Number
Description

PatientHospitalNumber

Data type

text

Participating Group Protocol No.
Description

ParticipatingGroupProtocolNo.

Data type

text

Main Member Institution/Adjunct
Description

MainMemberInstitution/Adjunct

Data type

text

Participating Group Patient No.
Description

ParticipatingGroupPatientNo.

Data type

text

Unnamed3
Description

Unnamed3

Histologically confirmed invasive carcinoma of the breast
Description

Histologicallyconfirmedinvasivecarcinomaofthebreast

Data type

text

Undergone either modified radical mastectomy or lumpectomy
Description

Undergoneeithermodifiedradicalmastectomyorlumpectomy

Data type

text

Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
Description

NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy

Data type

text

No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
Description

Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer

Data type

text

No involvement of dermal lymphatics on pathology
Description

Noinvolvementofdermallymphaticsonpathology

Data type

text

"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
Description

"High-risk"node-negativebreastcancer

Data type

text

Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
Description

Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative

Data type

text

No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
Description

Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy

Data type

text

Age >= 18 years
Description

Age>=18years

Data type

text

CTC Performance status 0-1
Description

CTCPerformancestatus0-1

Data type

text

Non-pregnant and non-nursing
Description

Non-pregnantandnon-nursing

Data type

text

No active congestive heart failure nor myocardial infarction within 6 months prior to registration
Description

Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration

Data type

text

Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Description

Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix

Data type

text

Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
Description

Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene

Data type

text

Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
Description

Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.

Data type

text

Date tamoxifen started
Description

Datetamoxifenstarted

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Date tamoxifen discontinued
Description

Datetamoxifendiscontinued

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Meets ALL of the following laboratory criteria completed within 16 days before registration
Description

MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration

Data type

text

ANC >= 1000/mcL
Description

ANC>=1000/mcL

Data type

text

Date obtained (ANC)
Description

Dateobtained(ANC)

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Platelets >= 100,000/mcL
Description

Platelets>=100,000/mcL

Data type

text

Date obtained (Platelets)
Description

Dateobtained(Platelets)

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Creatinine <= 2.0 mg/dL
Description

Creatinine<=2.0mg/dL

Data type

text

Date obtained (Creatinine)
Description

Dateobtained(Creatinine)

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
Description

TotalBilirubin<1.5xupperlimitsofnormaloflaboratory

Data type

text

Date obtained (Total Bilirubin)
Description

Dateobtained(TotalBilirubin)

Data type

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
ULN (Total Bilirubin)
Description

ULN(TotalBilirubin)

Data type

text

<= 84 days since last major breast surgery
Description

<=84dayssincelastmajorbreastsurgery

Data type

text

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist
Description

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Similar models

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Unnamed1
CALGBProtocolNumber
Item
CALGB Study No.
text
CALGBPatientID
Item
CALGB Patient ID
text
Item Group
Unnamed2
Patient'sName
Item
Patient's Name
text
ParticipatingGroup
Item
Participating Group
text
C17005 (NCI Thesaurus ObjectClass)
C1257890 (UMLS 2011AA ObjectClass)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
PatientHospitalNumber
Item
Patient Hospital Number
text
ParticipatingGroupProtocolNo.
Item
Participating Group Protocol No.
text
MainMemberInstitution/Adjunct
Item
Main Member Institution/Adjunct
text
ParticipatingGroupPatientNo.
Item
Participating Group Patient No.
text
Item Group
Unnamed3
Histologicallyconfirmedinvasivecarcinomaofthebreast
Item
Histologically confirmed invasive carcinoma of the breast
text
Undergoneeithermodifiedradicalmastectomyorlumpectomy
Item
Undergone either modified radical mastectomy or lumpectomy
text
NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy
Item
Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
text
Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer
Item
No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
text
Noinvolvementofdermallymphaticsonpathology
Item
No involvement of dermal lymphatics on pathology
text
"High-risk"node-negativebreastcancer
Item
"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
text
Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative
Item
Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
text
Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy
Item
No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
text
Age>=18years
Item
Age >= 18 years
text
CTCPerformancestatus0-1
Item
CTC Performance status 0-1
text
Non-pregnantandnon-nursing
Item
Non-pregnant and non-nursing
text
Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration
Item
No active congestive heart failure nor myocardial infarction within 6 months prior to registration
text
Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix
Item
Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
text
Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene
Item
Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
text
Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.
Item
Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
text
Datetamoxifenstarted
Item
Date tamoxifen started
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Datetamoxifendiscontinued
Item
Date tamoxifen discontinued
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration
Item
Meets ALL of the following laboratory criteria completed within 16 days before registration
text
ANC>=1000/mcL
Item
ANC >= 1000/mcL
text
Dateobtained(ANC)
Item
Date obtained (ANC)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Platelets>=100,000/mcL
Item
Platelets >= 100,000/mcL
text
Dateobtained(Platelets)
Item
Date obtained (Platelets)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Creatinine<=2.0mg/dL
Item
Creatinine <= 2.0 mg/dL
text
Dateobtained(Creatinine)
Item
Date obtained (Creatinine)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
TotalBilirubin<1.5xupperlimitsofnormaloflaboratory
Item
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
text
Dateobtained(TotalBilirubin)
Item
Date obtained (Total Bilirubin)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
ULN(TotalBilirubin)
Item
ULN (Total Bilirubin)
text
<=84dayssincelastmajorbreastsurgery
Item
<= 84 days since last major breast surgery
text
Item Group
Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial